IDELVION has been approved in Europe, becoming the first and only clotting factor IX therapy to be administered every 21 days

CSL Behring has announced that the European DrugAdministrationBureau (EMA) has approved its new long-acting recombinant albumin fusion IX coagulation factor IDELVION (albutrepenonacog alfa) for the treatment of type B haemophiliaapproval makes IDELVION the first and only IX factor therapy that can be administered every 21 daysDr Lutz Bonacker, senior vice president of CSL Behring Europe, added: "We have listened to patients and hope to offer treatment options with a time of more than 14 daysWe are proud to be the only company to offer long-lasting IDELVION products that reduce the patient's treatment burden and provide flexibility"
aboutof haemophilia type B
haemophilia type B is a congenital haemorrhagic disease characterized by insufficient or defective coagulation factor IXAlmost all of the affected patients were malePeople with type B haemophilia may experience prolonged or spontaneous bleeding, especially in muscles, joints or internal organsAccording to the U.SCenters for Disease Control,prevention , the incidence of the disease is about one in 25,000 male babies on the treatment and prevention of haemorrhage in patients with IDELVION IDELVION IDELVION is a fusion recombinant albumin extension factor IX, the choice of recombinant albumin is due to its good tolerance, the the likelihood of the primary reaction, and the removal mechanism is clear